Compare EEIQ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | OGEN |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.6M |
| IPO Year | 2019 | 2010 |
| Metric | EEIQ | OGEN |
|---|---|---|
| Price | $4.00 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 63.9K |
| Earning Date | 01-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.11 |
| 52 Week High | $12.70 | $9.16 |
| Indicator | EEIQ | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 45.06 |
| Support Level | $0.35 | $0.61 |
| Resistance Level | $12.70 | $1.02 |
| Average True Range (ATR) | 0.73 | 0.06 |
| MACD | -0.29 | 0.01 |
| Stochastic Oscillator | 8.27 | 35.72 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.